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Pyridoxine-dependent epilepsy (PDE) is an inherited disease with an autosomal recessive trait caused by deficiency of α-
amino-adipic semialdehyde (AASA) dehydrogenase encoded by the ALDH7A1 gene. Pyridoxine administration is usually ef-
fective for the treatment of PDE. We identified compound heterozygous ALDH7A1 mutation in a patient with undiagnosed
intractable epilepsy. One of the mutations was located in the splicing region of this gene. We analyzed the RNA expression
patterns and confirmed the hemi-allelic expression of this gene, which could be considered a consequence of erroneous splic-
ing, though this was not direct evidence of a splicing error. The severe developmental delay observed in this patient could
have been avoidable by prompt treatment intervention in the early neonatal period. Therefore, it is important to remind that
vitamin B6 should be prescribed for neonatal patients with clustering seizures occurring soon after birth.
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Introduction
Pyridoxine-dependent epilepsy (PDE; MIM#266100) is
an inherited disease with an autosomal recessive trait.
PDE is caused by a deficiency of α-amino-adipic semial-
dehyde (AASA) dehydrogenase that is encoded by alde-
hyde dehydrogenase 7 family, member A1 gene:
ALDH7A1, also known as antiquitin-1.１ Reduced activity
of AASA dehydrogenase due to ALDH7A1 abnormality
leads to accumulation of piperideine-6-carboxylate
(P6C), which is a metabolite of lysin.
２
An increased level
of P6C causes inactivation of pyridoxal phosphate (PLP),
which is a vitamin B6-dependent activator and a coen-
zyme of many enzymatic reactions, including amino ac-
ids transfer, hydrolysis, and decarboxylation. Thus, sei-
zures in PDE are most probably due to the increased
metabolic activity in the brain. Although many types of
ALDH7A1 mutations have been previously reported,
there is no common mutation found in this gene.
３
Here,
we identified a rare compound heterozygous ALDH7A1
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Figure　1　T2-weighted brain magnetic resonance imaging (MRI)
examined at 7 months. Diffuse brain atrophy is noted.
Rt
Figure　2　Electroencephalogram (EEG) examined at 3 years shows multiple sharp wave bursts.
mutation in a Japanese patient with PDE.
Case Report
A 7-year-old boy was born at 37 weeks of gestation
weighing 2.66 kg with 34 cm of appropriate occipitofron-
tal circumference through an emergency cesarean section
due to a variable deceleration of fetal heart rate without
asphyxia. He is the second child of unrelated healthy par-
ents and his elder sister is also healthy. He needed to be
admitted to the neonatal intensive care unit owing to
signs of irritating and cramps which were observed soon
after birth. Momentary motions appeared intermittently,
and epileptic seizures were confirmed by electroencepha-
logram. The boy was then treated with continuous intra-
venous injections of midazolam (MDZ). Valproate and
clobazam were administered and the epileptic seizures
were controlled. He was discharged from hospital on day
61 after his birth. However, at 6 months of his life, epi-
leptic seizures with hemi-lateral convulsion were ob-
served, and intra-venous MDZ infusion was again initi-
ated. Brain magnetic resonance imaging (MRI) examined
at 7 months of age showed ventricular enlargement with
diffuse atrophy of the cerebral cortex (Figure 1), which
were retrospectively evaluated as compatible to those of
the patients with PDE.
４
The intractable spasm-like sei-
zures were controlled by administration of vitamin B6.
An electroencephalogram, obtained at the age of 3 years
showed bilateral temporal dominant sharp waves (Fig-
ure 2). Then, control of epileptic seizures was solely de-
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Figure　3　Results of molecular analyses. (A) The intronic muta-
tion, c.108+3A>T, is shared with the mother. (B) The missense
mutation, c.890C>T, identified in the patient is common with the 
father. This indicates compound heterozygous mutation in AL-
DH7A1. (C) Reverse transcribed-PCR (RT-PCR) assay followed 
by Sanger sequencing demonstrates only “T” in exon 11, indicat-
ing that the maternally derived allele is not expressed (hemi-allelic
expression).
Table　1　Results of metabolic examination.
Blood serum
Pipecpli acid 6.6 μmol/L (0.4-2.0)
α-AASA 8.0 μmol/L (<0.2)
Cerebrospinal fluid
Pipecpli acid 1.8 μmol/L (<0.1)
α-AASA 5.6 μmol/L (<0.1)
α-AASA, α-amino-adipic semialdehyde.
Table　2　Prediction scores of the identified 
variant.
Chromosome chr5
Position 125894966
Reference nucleotide G
Altered nucleotide A
SIFT_score 0
SIFT_pred D
Polyphen2_HDIV_score 0.967
Polyphen2_HDIV_pred D
LRT_score 0
LRT_pred D
MutationTaster_score 1
MutationTaster_pred D
CADD_phred 27.5
SIFT, sorting intolerant from tolerant; pred, 
predication; PolyPhen, polymorphism pheno-
typing; LRT, likelihood ratio test; CADD, com-
bined annotation dependent depletion; phred, 
one of the base-calling programs; D, damaging
pendent on the dosage of administered vitamin B6. Thus,
vitamin B6-dependent epilepsy was suspected when the
patient was 7 years old. Metabolic analyses of the blood
and cerebrospinal fluid were performed at Okayama Uni-
versity.
５
Elevated levels of pipecolic acid and α-AASA
were then confirmed (Table 1). His psychomotor devel-
opment has been severely delayed; head control was ob-
tained at 4 months, but he cannot sit or stand by himself
at present. He shows no verbal communication.
From these clinical findings as well as the medical
treatment courses, ALDH7A1 was suspected as the causal
candidate gene. After obtaining written informed consent
from his parents, blood samples were withdrawn from
the patient and his parents. This study was performed in
accordance with the Declaration of Helsinki and was ap-
proved by the Gene Analysis Research Ethics Committee
of Tokyo Women’s Medical University ( No. 341B) .
Genomic DNA was extracted from peripheral blood of
the patient and his parents using a QIAamp DNA extrac-
tion kit (Qiagen, Hilden, Germany). Polymerase chain re-
action (PCR) and subsequent Sanger sequencing for all
exons and exon-intron boundaries of ALDH7 A 1 were
performed.
A paternally derived missense variant, NM_
001201377.1: c.890C>T [p.Thr297Ile], was identified in
exon 11 (Figure 3B), which has already been reported.６
Previously, a similar type of a nucleotide alteration,
c.890C>G [p. Thr297 Arg ] , was also reported as the
disease-causing mutation.
７
“Damaging scores” of p.Thr
297Ile were predicted through wANNOVAR (http://wan
novar.wglab.org/), a web-based software (Table 2). Most
of the scores suggested having a high probability of
“damaging”. Especially, combined annotation dependent
depletion (CADD)_phred was scored as “27.5”. Thus, we
considered this as the deleterious mutation.
A maternally derived intronic variant, NM_
001201377.1: c.108+3A>T, was also identified in intron
1 (Figure 3 A ) , which has already been identified.８
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However, the splicing abnormality has never been
confirmed for this variant. We analyzed the possibility of
a splicing abnormality in this variant by using an in-silico
bioinformatics tool, Human Splicing Finder (http://umd.
be /HSF 3 / ) , which indicates that this intronic variant
“most probably affecting splicing” by breaking splicing
donor site.
To confirm splicing abnormality by this intronic
variant, we performed a reverse transcribed-PCR (RT-
PCR), using primers located on the neighboring exonic
regions. A total RNA was extracted from leukocytes for
RT-PCR, as described previously.
９
Our mRNA analysis
did not find any abnormal splicing patterns.
Alternatively, only hemi-allelic expression of exon 11
was confirmed by RT-PCR and subsequent Sanger
sequencing of this region (Figure 3 C ) . The results
indicate that only the paternally derived allele was
expressed in this region and there was no expression of
the maternally derived allele.
Discussion
In this study, successful treatment with vitamin B6 for
PDE was a clue to ascertain a final diagnosis of PDE in a
7-year-old patient. However, most of the PDE patients,
who are treated with vitamin B6 soon after the onset of
seizures in the neonatal period, show normal
developmental milestones. Thus, had this patient
received prompt therapeutic intervention during his
neonatal period, severe developmental delay in this
patient might have been avoidable. Therefore, it is
important to remind that vitamin B6 should be prescribed
for neonatal patients with clustering seizures occurring
soon after birth.
Compound heterozygous ALDH7A1 mutation was
confirmed in the present patient. One of the mutations, p.
Thr297 Ile, was inherited from his father. Whereas, a
suspected splicing mutation, c.108+3A>T, was inherited
from his mother. Both mutations have already been
reported previously.
６，８
However, it was unclear whether
the possible splicing mutation (c. 108 +3 A>T ) would
really cause a splicing abnormality. Thus, we examined
to confirm if there were abnormal splicing patterns in
mRNA.
As a result, we could not get direct evidence of
abnormal splicing derived from an intronic variant c.108
+ 3 A > T. Alternatively, the hemi-allelic expression in
exon 11 region was confirmed, which will cause a similar
effect with a homozygous mutation. Taken together, the
hemi-allelic expression may be the essential reason for
PDE in this patient, thought we were unable to provide
any evidence of abnormal splicing patterns from an
intronic mutation.
Acknowledgements
The authors would like to express gratitude for the patient and
his family for their cooperation. This work was supported by
the Practical Research Project for Rare/Intractable Diseases
from the Japan Agency for Medical Research and
development ( AMED ) , and a Grant-in-Aid for Scientific
Research from the Health Labor Sciences Research Grants
from the Ministry of Health, Labor and Welfare, Japan, and
JSPS KAKENHI for Toshiyuki Yamamoto. We are also
thankful for the support from the Initiative on Rare and
Undiagnosed Diseases (IRUD) via AMED.
Conflicts of Interest: There is no conflict of interest for
any of the authors.
References
1．Mills PB, Struys E, Jakobs C et al: Mutations in
antiquitin in individuals with pyridoxine-dependent
seizures. Nat Med 12: 307―309, 2006
2．Plecko B, Paul K, Paschke E et al: Biochemical and
molecular characterization of 18 patients with
pyridoxine-dependent epilepsy and mutations of the
antiquitin (ALDH7A1) gene. Hum Mutat 28: 19―26,
2007
3．Mills PB, Footitt EJ, Mills KA et al: Genotypic and
phenotypic spectrum of pyridoxine-dependent epilepsy
(ALDH7A1 deficiency). Brain 133: 2148―2159, 2010
4．Toldo I, Bonardi CM, Bettella E et al: Brain
malformations associated to Aldh7a1 gene mutations:
Report of a novel homozygous mutation and literature
review. Eur J Paediatr Neurol 22: 1042―1053, 2018
5．Akiyama T, Akiyama M, Hayashi Y et al: Measurement
of pyridoxal 5’-phosphate, pyridoxal, and 4-pyridoxic
acid in the cerebrospinal fluid of children. Clin Chim
Acta 466: 1―5, 2017
6．Friedman SD, Ishak GE, Poliachik SL et al: Callosal
alterations in pyridoxine-dependent epilepsy. Dev Med
Child Neurol 56: 1106―1110, 2014
7．Gallagher RC, Van Hove JL, Scharer G et al: Folinic
acid-responsive seizures are identical to pyridoxine-
dependent epilepsy. Ann Neurol 65: 550―556, 2009
8．Kanno J, Kure S, Narisawa A et al: Allelic and non-
―77―
allelic heterogeneities in pyridoxine dependent seizures
revealed by ALDH7A1 mutational analysis. Mol Genet
Metab 91: 384―389, 2007
9．Yamamoto-Shimojima K, Imaizumi T, Aoki Y et al:
Elucidation of the pathogenic mechanism and potential
treatment strategy for a female patient with spastic
paraplegia derived from a single-nucleotide deletion in
PLP1. J Hum Genet 64: 665―671, 2019
